Observational South Korean study shows no association with adverse outcomes if antiplatelet therapy is 4-8 days
A large, real-world registry from Korea demonstrates that antiplatelet therapy (APT) with second-generation drug-eluting coronary stents (DES) is commonly discontinued during non-cardiac surgery (NCS), but this is not necessarily related to an increase in major adverse cardiac events (MACE) or major bleeding events.